Aprea Therapeutics Q3 2026 Earnings Date & Estimates

Aprea Therapeutics (NASDAQ:APRE) (NASDAQ: APRE) is a clinical-stage biopharmaceutical company developing targeted therapies for cancer. Its research focuses on treatments designed to exploit weaknesses in tumor cells, with an emphasis on DNA damage response and cell-cycle regulation.

The company’s lead investigational program is ATRN-119, an oral, selective inhibitor of ataxia telangiectasia and Rad3-related protein, or ATR. ATRN-119 is being evaluated in early-stage clinical studies for patients with advanced solid tumors. ATR inhibition is intended to interfere with cancer cells’ ability to repair damaged DNA, potentially making them more vulnerable to treatment.

Aprea has historically developed therapies targeting the tumor-suppressor protein p53, including eprenetapopt, also known as APR-246, for hematologic malignancies such as myelodysplastic syndromes and acute myeloid leukemia. The company’s current development strategy is centered on advancing its DNA damage response pipeline through clinical development. Aprea is headquartered in the United States and conducts research and clinical development through collaborations and study sites serving patients in relevant oncology markets.